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1149-13 Angiographic and Clinical Outcome After Implantation 
of the Low-Pressure LP TM Stent: Results of the 
CONSERVE Trial 
Sorin J. Brener, Donnel Murphy, Eric J. Topoi, Cleveland Clinic Foundation, Cleveland, 
Ohio. 
Background: Coronary stent implantation induces neo-intimal hyperplasia, which is 
responsible for restenosis. It is not known whether the barotrauma ssociated with high- 
pressure stent deployment contributes to this phenomenon. Thus, we compared the 
angiographic and clinical outcome of low (10-12 atm) pressure stent implantation of a 
new stainless steel stent design (LP TM) with conventional high-pressure deployment in 
the CONSERVE trial. Methods: One thousand and four patients with symptomatic coro- 
nary artery disease (excluding recent infarction) and de novo or restenotic lesions in 
native coronary arteries, measudng 3-4 mm. in diameter were randomized in an open- 
label fashion to the LP or Guidant stant. Pre-dilatation was required for all lesions. Anglo- 
graphic follow-up at 6 months was performed in the first 150 patients randomized to the 
LP stent. The primary endpoint was clinically driven target vessel revascularization (TVR) 
at 6 months. Additional endpoints included ability to deploy the stent, angiographic rest- 
enosis, and major adverse ischemic events. Results: Based on data from the first 617 
patients (presented in aggregate) with 704 lesions and 730 stents, the mean age was 
62+11 years and 72% were male. LAD lesions were treated in 38% and 82% of all 
lesions were type B/C lesions. The reference diameter was 3.3+0.4 mm. and the length 
was 12.5+5 mm. Pre-stenosis was 86+10% and post-stenosis was 2+7%. Stant dsploye- 
ment was attempted in 98.9% and successful in 98.7% with post-dilatation i 58%. At 7 
days, 6.7% of patients achieved an ischemic endpoint (death - 0%, MI - 6.3%, CABG - 
0.3%, urgent TVR - 0.6%). At 6 months, TVR occurred in 5.3%. Conclusions: Complete 
angiographic (including inflation pressure) and clinical data for each treatment arm will be 
avilable at the time of the presentation, after completion of the follow-up in the entire 
cohort. 
1149-14 Clinical Outcome in Patients Undergoing Stenting of 
Saphenous Vein Grafts Using the TriActiv TM Balloon- 
Protection System: Initial U.S. and European 
Experience 
Joseoh P. Carrozza. Jr.. Bernard Lancelin, Chdstophe Caussin, Peter Braun, William 
Kussmaul, Barry George, Barry Uratsky, Gregory Braden, Beth Israel Deaconess 
Medical Center, Boston, Massachusetts. 
Background. Stanting of saphenous vein grafts (SVGs) with distal protection reduces 
embolization and adverse clinical events. The TriActiv TM System is a next-generation 
distal protection system using balloon occlusion and active particle removal through a 
pump-driven flush and extraction system.. 
Methods. 37 SVG lesions in 25 patients in the US and Europe have undergone stenting 
with distal protection using the TdActiv TM System. 
Results. Baseline demographics are shown in the Table. Mean balloon occlusion time 
was 278 secs. Procedural success (device success without in-hospital death, MI, stroke, 
or revascularization) was 84%. There were 3 cases of failure to cress the lesion with the 
protection balloon guidewire and 1 non-Q-wave MI. Follow-up at 30 days was available 
for the first 10 patients. There were no deaths, Q-wave MI, emergency revasculadza- 
tions, or strokes, and only 1 patient (stantad without distal protection) suffered a non-Q- 
wave MI. 
Conclusions. Stenting of SVGs with the TriActiv TM System is associated with a high rate 
of procedural success and low incidence of adverse events. 30 day outcome for the 
entire cohort will be presented. 
Baseline Demographics 
Patient age (yrs) 66 
Graft age (yrs) 9.8 
Diabetes Mellitus (%) 28 
Prior MI (%) 48 
Pre-treatment diameter stenosis (%) 83 
Lesion length (ram) 18.4 
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1149-15 Fate of Side Branches After Sirolimus-Eluting Stant 
Implantation 
Kenoo Taoabe, M. Degertekin, J. E. Sousa, J. Fajadet, M. Perin, E. Ban Hayashi, A. 
Colombo, M. C. Modca, P. W. Serruys, E. Wulfert, Thoraxcanter, Rotterdam, The 
Netherlands. 
Background; Sirolimus-eluting stent (SES) is emerging as a potential solution for the 
prevention of restenosis. The fate of side branches (SB) after coronary angioplasty with 
uncoated stents (US) has been reported, but the outcome of SB after SES implantation is
unknown. Furthermore, the absence of reopening of occluded SB following intracoronary 
brachytherapy has been previously described and related to a delayed healing process. 
The objective of this subanalysis is to investigate the fate of SB in the RAVEL study, a 
double- blind, controlled trial of Sirolimus-eluting Bx VELOCITY ~m stent (Cordis, Water- 
loo, Belgium) vs uncoated Bx VELOCITY rm stent. 
Methods: We assessed the procedural and 6-month follow-up angiograms of 212 
patients enrolled in the RAVEL study. Any visible SB seen on the pre-stent angiogram 
and covered by the stent was assessed for occlusion at baseline and reopening at 6 
months by two observers blinded to treatment. 
Results: 128 patients with one or more side branches originating from the target area 
were identified. (63 patients in SES group with 118 SB, 65 patients in US group with 124 
SB). QCA data of target lesion and fate of SB are descdbed below. 
SES US P-value 
lesion N=63 N=65 
RD pre (mm) 2.63t-0.53 2.68_+0.58 NS 
MLD pre (mm) 0.87_+0.33 0.98+_0.39 NS 
MLD post (ram) 2.48_+0.41 2.42+-0.46 NS 
MLD 6-month (ram) 2.40+0.48 1.63_+0.59 .000 
SB n=118 n=124 NS 
occlusion 10 % (12/118) 7 % (9/124) NS 
reopen 92 % (11/12) 67 % (6 /9 )  NS(p=0.15) 
Conclusion: With the limited number of observations made in this study, the difference 
between SES and US in outcome of SB fails to be statistically significant. However, the 
trend (p=0.15) toward reopening observed in SES (92% versus 67%) warrants further 
investigation. 
1149-1 6 Predictors of Adverse Cardiac Events Following Beta 
Brechytherepy for In-Stent Restenosis 
Philio Urban. Patrick Serruys, Dietrich Baumgart, Antonio Colombo, Sigmund Silber, Eric 
Eeckhout, Hans Heuer, Kad Heinz Kuck, Thomas Schiele, Karl Weigscheider, Raoul 
Bonan, for the RENO Investigators, La Tour Hospital, Meyrin-Geneva, Switzerland. 
The RENO registry is a database of patients treated by intracoronary radiotherapy using 
the Novoste Beta-Cath TM system at 46 centers in Europe and the Middle East in 1999- 
2000. From a total of 1098, 878 patients (77.7%) were treated for at least one in-stent 
restenotic lesion. In this subset, the technical success rate was 95.7%. 19+3 Grays were 
delivered to 928 lesions with a reference diameter of 3.2 + 0.5 mm and a length of 19.4 + 
12.3 mm. A new stant was used in 18.4% of lesions, and combined antiplatelet treatment 
was generally given for 6-12 months. Clinical follow-up data were available for 869 (99%) 
patients after 6.3 + 2.4 months. The major adverse cardiac event (MACE) rate was 
17.7% (death of any cause 2.f%, AMI 2.4%, TVR 15.4%). We used multivadate analysis 
to identity predictors of MACE in 794 patients with single vessel procedures. 
Diabetes was not predictive of 6 month MACE. 
These data demonstrate that the good results of randomized tdals can be replicated in 
routine clinical practice. The availability of MACE predictors may help better select 
patients and adapt he use of concomitant PCI modalities. 
Multivariate predictors 
MACE Predictor OR 95% CI 
Age (1 year older) 0.978 0.960-0.996 
Unstable angina 1.703 1.108-2.616 
Native (rather than vein 0.366 0.173-0.772 
graft) 
Lesion length (t mm longer) 1,015 1.001-1.030 
Ref. diameter (1 mm more) 0.614 0.401-0.940 
Cutting balloon use 0.491 0.269-0.896 
New stent implantation 1.624 1.023-2.577 
